Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura
M
M
Department of Pharmacy, Akita University Hospital, 1-1-1 Hondo, 010-8543, Akita, Japan.
Tada
H
H
Yasui-Furukori
N
N
Uno
T
T
Sugawara
K
K
Tateishi
T
T
Suzuki
T
T
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D064748:Dexlansoprazole; D005260:Female; D005838:Genotype; D006207:Half-Life; D006801:Humans; D064747:Lansoprazole; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000097:blood* / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics*; D054328:Proton Pump Inhibitors; D013237:Stereoisomerism; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; C581535:Lansoprazole Sulfone; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole; C498264:5-hydroxylansoprazole; D064748:Dexlansoprazole